Scientists alarmed by vaccine makers’ ‘secrecy’ about trials

  • Scientists alarmed by vaccine makers’ ‘secrecy’ about trials

Scientists alarmed by vaccine makers’ ‘secrecy’ about trials

Fatigue was the most commonly reported symptom data as of August 27, executives said on an investor conference call on Tuesday.

Speaking to Russian newspaper Izvestia, Murashko explained that more than 300 people have already received the Sputnik V vaccine as part of the three-phase trial, and 14 percent have complained about their health.

No major side effects, such as adverse reactions that require hospitalization, have been reported.

"These are predicted side effects, and they usually disappear after a day, or at maximum, a day and a half", the minister said.

The late-stage clinical trial for AstraZeneca's COVID-19 vaccine will be suspended in the USA for at least several more days, Reuters reported Monday, citing a source familiar with the matter.

"We're here to protect the American public and we're going to do very significant work with the company to figure out if there's a significant safety issue or not", Hahn said.

"I can not say what the FDA will do", Bourla said.

Novavax Inc last month separately said SK Bioscience, a unit of SK Chemicals, would manufacture a component of the US drug developer's experimental coronavirus vaccine in a bid to boost its supply.

Bourla told the media that the company releasing data is "very unusual" but called it a "must" due to ongoing discussions with the U.S. government and regulators.

AstraZeneca's AZN.L COVID-19 vaccine trial remains on hold in the United States pending a USA investigation into a serious side effect in Britain even as other trials of the vaccine resume, sources familiar with the details told Reuters. That is expected to trigger in turn an immune response so the body can fight off any future COVID-19 infection.

Japan has also pursued independent arrangements with global pharmaceutical companies to secure vaccines, with the government pledging to have enough supply for the whole population by the first half of 2021.

Volunteers given either the low or medium dose generated not just antibodies against the virus but specifically neutralizing antibodies, meaning they stop the virus from infecting human cells.

An official the Chinese Centre for Disease Control and Prevention, Guizhen Wu, has said the coronavirus vaccines being developed in China may be ready for use by the general public as early as November, 2020.